• 1
    Shivananda S, Lennard-Jones J, Logan R, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut. 1996; 39: 690697.
  • 2
    Vind, I, Riis L, Jess T, et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003–2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol. 2006; 101: 12741282.
    Direct Link:
  • 3
    Cornish JA, Tan E, Teare J, et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut. 2007; 56: 830837.
  • 4
    Mahadevan U, Sandborn WJ, Li DK, et al. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study of Northern California. Gastroenterology. 2007; 133: 11061112.
  • 5
    Nguyen GC, Boudreau H, Harris ML, et al. Outcomes of obstetric hospitalizations among women with inflammatory bowel disease in the United States. Clin Gastroenterol Hepatol:. 2009; 7: 329334.
  • 6
    Dominitz, JA, Young JC, Boyko EJ, et al. Outcomes of infants born to mothers with inflammatory bowel disease: a population based cohort study. Am J Gastroenterol. 2001; 96: 635643.
  • 7
    Kornfeld D, Cnattingius S, Ekbom A. Pregnancy outcomes in women with inflammatory bowel disease—a population-based cohort study. Am J Obstet Gynecol. 1997; 177: 942946.
  • 8
    Fonager K, Sorensen HT, Olsen J, et al. Pregnancy outcome for women with Crohn's disease: a follow-up study based on linkage between national registries. Am J Gastroenterol. 1998; 93: 24262430.
    Direct Link:
  • 9
    Baird DD, Narendranathan M, Sandler RS. Increased risk of preterm birth for women with inflammatory bowel disease. Gastroenterology. 1990; 99: 987994.
  • 10
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359: 15411549.
  • 11
    Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl Med. 2005; 353: 24622476.
  • 12
    Sandborn WJ, Hanauer SB, Rutgeerts PJ, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II Trial. Gut. 2007; 56: 12321239.
  • 13
    Hanauer SB, Lukas M, MacInthosh D, et al. A randomized, double-blind, placebo-controlled trial of the human anti-TNF-a monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn's disease. Gastroenterology. 2006; 130: 323333.
  • 14
    Johnson DL, Jones KL, Chambers CD, et al. Pregnancy outcomes in women exposed to adalimumab: the OTIS autoimmune diseases in pregnancy project. Gastroenterology. 2009; 136: A27.
  • 15
    Mahadevan U, Kane S, Sandborn WJ, et al. Intentional infliximab use during pregnancy for induction or maintenance of remission of Crohn's disease. Aliment Pharmacol Ther. 2005; 21: 733738.
  • 16
    Katz JA, Antoni C, Keenan GF, et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol. 2004; 99: 23852392.
    Direct Link:
  • 17
    Tursi A. Effect of intentional infliximab use throughout pregnancy in inducing and maintaining remission in Crohn's disease. Dig Liver Dis. 2006; 38: 437440.
  • 18
    Simister NE. Placental transport of immunoglobulin G. Vaccine. 2003; 21: 365369.
  • 19
    Vasiliauskas EA, Church JA, Silvermann N, et al. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol. 2006; 4: 12551258.
  • 20
    Lichtenstein GR, Cohen RD, Fegan BG, et al. Safety of Inliximab in Crohn's disease: data from the 5000 patient TREAT registry. Gastroenterology. 2004; 126: A54.
  • 21
    Vinet E, Pineau C, Gordon C et al. Biologic therapy and pregnancy outcomes in women with rheumatic diseases. Arthritis Rheumatism. 2009; 61: 587592.
  • 22
    Thompson AM, Bizzarro MJ. Necrotizing enterocolitis in newborns: pathogenesis, prevention and management. Drugs. 2008; 68: 12271238.
  • 23
    Jones RH, Xu S, Grunwald GK. Continuous time Markov models for binary longitudinal data. Biometr J. 2006; 48: 411419.
  • 24
    Cater JD, Ladhani A, Ricca LR, et al. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol. 2009; 36: 635641.
  • 25
    Winger EE, Reed JL. Was risk properly assessed in Carter, et al's safety assessment of tumor necrosis factor antagonists during pregnancy? J Rheumatol. 2009; 36: 9.